Evidence map›Paper›PMID 36249245›Full record

ArticleFrontiers in public health2022

Evaluating the role of SARS-CoV-2 target genes based on two nucleic acid assay kits.

Xuetong Zhu, Fengyan Zhou, Qi Zhou, Jiancheng Xu

Open access · goldAbstract read
In one paragraph

Article in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Xuetong ZhuCenter of Infectious Diseases and Pathogen Biology, The First Hospital of Jilin University, Changchun, China.
Fengyan ZhouDepartment of Infectious Disease Control, Jilin City Center for Disease Control and Prevention, Jilin, China.
Qi ZhouCenter of Infectious Diseases and Pathogen Biology, The First Hospital of Jilin University, Changchun, China.
Jiancheng XuCenter of Infectious Diseases and Pathogen Biology, The First Hospital of Jilin University, Changchun, China.
First Hospital of Jilin University · CNCenter for Disease Control · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Effective isolation and early treatment of coronavirus disease 2019 (COVID-19) relies on rapid, accurate, and straightforward diagnostic tools. In response to the rapidly increasing number of cases, reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assays for multiple target genes have become widely available in the market. Methods: In total, 236 COVID-19 patients with positive results in both RT-qPCR and rapid antigen diagnosis (Ag-RDT) were enrolled in the study. The cycle threshold (Ct) was compared with different onset times and target genes. Comparison between groups was evaluated with the Kruskal-Wallis test and Dunn test. The correlation between target genes was analyzed by Spearman. Results: In samples of Ct ≤ 21, Ct was different for the nucleocapsid (N), open reading frame 1ab (ORF1ab), and envelope (E) genes ( Conclusion: RT-qPCR confirmed that the N gene performed well in Ct ≤ 21 and samples within 7 days of onset. Ag-RDT was discriminatory for patients within 7 days of onset. This study facilitated early identification and control of COVID-19 prevalence among patients.

Indexed as

COVID-19Nucleic AcidsHumansPolymethacrylic AcidsSARS-CoV-2Sensitivity and SpecificityNucleic AcidsPolymethacrylic Acidsantigen rapid diagnostic testcoronavirus disease 2019nucleocapsid genereverse transcription-quantitative polymerase chain reactionsevere acute respiratory syndrome coronavirus 2

Identifiers

PMID36249245
PMCPMC9554243
OpenAlexW4297329533

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.